Literature DB >> 7139526

Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma.

G A Gomez, K K Aggarwal, T Han.   

Abstract

In a prospective randomized study of treatment with radiation therapy (RT) or RT + chemotherapy (CT) for patients with non-Hodgkin's lymphoma Stages I-III, one patient developed an acute malignant myeloproliferative syndrome (AMMS) and four others acute nonlymphocytic leukemia (ANLL). There was correlation between the intensity of treatment and development of this complication: Among patients treated with local radiation with or without chemotherapy no cases of AMMS or ANLL were observed. However, patients treated with total lymphoid irradiation alone (TLI) had an observed to expected ratio of 162. Among patients treated with TLI plus CT this ratio increased to over 1000. The cytogenetic, clinical, and hematologic abnormalities of these patients are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139526     DOI: 10.1002/1097-0142(19821201)50:11<2285::aid-cncr2820501111>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.

Authors:  Mojtaba Akhtari; Vijaya Raj Bhatt; Pavan Kumar Tandra; Jairam Krishnamurthy; Heidi Horstman; Amy Dreessen; Pei Xian Chen; James O Armitage
Journal:  Cancer Biol Ther       Date:  2013-10-18       Impact factor: 4.742

2.  Acute leukemia in a patient cured of diffuse histiocytic lymphoma.

Authors:  J P Dutcher; P H Wiernik
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL).

Authors:  G Sozzi; M Miozzo; A Orazi; C Calderone; M Castellano; S Viviani; A Santoro; M A Pierotti; G Della Porta
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.